Sonoma Pharmaceuticals, Inc. - SIC # 2647 -

Ticker Exchange SIC # Website Latest Ticker
SNOA Nasdaq 2647 sonomapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Aug 6th, 2026 7:00 am
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - Jun 30th, 2026 7:00 am
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - Jun 16th, 2026 2:15 pm
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering - Apr 24th, 2026 7:21 am
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart - Mar 24th, 2026 6:30 am
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin - Mar 18th, 2026 6:30 am
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results - Feb 10th, 2026 2:10 pm
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf - Nov 6th, 2025 2:01 pm
Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals - Oct 14th, 2025 6:30 am
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA - Oct 7th, 2025 6:30 am